GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akeso Inc (HKSE:09926) » Definitions » Revenue

Akeso (HKSE:09926) Revenue : HK$4,951 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Akeso Revenue?

Akeso's revenue for the six months ended in Dec. 2023 was HK$929 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$4,951 Mil. Akeso's Revenue per Share for the six months ended in Dec. 2023 was HK$1.11. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$5.91.

During the past 12 months, the average Revenue per Share Growth Rate of Akeso was 421.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 6 years, Akeso's highest 3-Year average Revenue per Share Growth Rate was 339.30% per year. The lowest was 122.50% per year. And the median was 230.90% per year.


Akeso Revenue Historical Data

The historical data trend for Akeso's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akeso Revenue Chart

Akeso Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial 78.87 - 276.27 935.42 4,950.72

Akeso Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 118.81 191.23 753.25 4,021.68 929.05

Competitive Comparison of Akeso's Revenue

For the Biotechnology subindustry, Akeso's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akeso's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akeso's Revenue distribution charts can be found below:

* The bar in red indicates where Akeso's Revenue falls into.



Akeso Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$4,951 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akeso  (HKSE:09926) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Akeso Revenue Related Terms

Thank you for viewing the detailed overview of Akeso's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Akeso (HKSE:09926) Business Description

Traded in Other Exchanges
Address
6 Shennong Road, Torch Development Zone, Guangdong Province, Zhongshan, CHN, 528437
Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China.

Akeso (HKSE:09926) Headlines

No Headlines